January 26, 2019 : Issue #974

• Glycemic Variability and Development of Retinopathy
• More Reasons To Use Statins For Diabetes Treatment
• Can AI Detect Diabetic Retinopathy More Accurately?
• Living With Family Obesity Raises Risk for Type 2 Diabetes
• Comparative Efficacy of Insulin Pumps vs Multiple Daily Injections for Pregnant Patients with Type 1 Diabetes
• Interrupting Sedentary Behavior with Physical Activity Has Benefits

Now that the cold cold weather of winter is upon us I am especially glad I live in Florida. As I am writing this, it is a chilly 61 degrees. Although most of you would love for it to be that warm where you are, there are some problems in paradise. This temperature is not cold enough for the heater to run all the time and so believe it or not, the air gets chilly, and as I am working at my desk my feet, hands and body get cold.

I think this is because my metabolism slows down and I am not creating body heat or burning fuel. I combat this by getting up from my desk and either moving around or doing some simple jumping jacks next to my desk. Just 2 or 3 minutes and my body feels warmer, and I am ready to sit back down.

This same idea seems to be valuable for children who have excess weight and obesity to help them control their glucose and their weight. Check out Item #6 and see if you think “jumping jacks” are the answer.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Would you consider recommending a CGM for your patients who have prediabetes and obesity? Follow the link to share your opinion and see what your colleagues think.

For the first time a research team will develop a pregnancy-specified artificial pancreas. Carol J. Levy, MD, CDE, Clinical Director of the Mount Sinai Diabetes Center, who is on DiabetesInControl’s Advisory Board and has managed the care of hundreds of pregnant women with this condition, serves as the project’s principal investigator at the Icahn School of Medicine at Mount Sinai.  Dr. Levy stated:

“Achieving and maintaining the very narrow range blood glucose levels required for the best fetal outcomes for pregnant women with type 1 diabetes is extremely challenging, even with optimal clinical care. The use of customized technology provides an important opportunity to improve patient and fetal outcomes. We are excited to be part of the team evaluating this important area of research designed to improve care and reduce patient burden.”      

Click here to view the press release: NIH Funds First Artificial Pancreas Study in the United States for Pregnant Women

The brand name Glucophage and Glucophage ER is being discontinued by the manufacturer.

A real-time CGM that is factory calibrated, the latest device has extended wear time that is fully disposable with simple application and a significantly lower cost. It is expected to be made available in 2020.

According to a recent study, which of the following is true among patients with type 2 diabetes (T2DM) and recent acute coronary syndrome (ACS)?

A. The risk for major adverse cardiovascular events (MACE) significantly increased with systolic blood pressure (SBP) less than 130 mm Hg.
B. The risk for MACE significantly increased with diastolic BP (DBP) less than or equal to 80 mm Hg.
C. The risk for MACE significantly decreased with SBP less than 130 mm Hg.
D. The risk for MACE significantly decreased with DBP less than or equal to 80 mm Hg.
E. A&B
F. C&D

Follow the link for the answer.

There is a popular misconception that SGLT2 inhibitors cause urinary tract infections, especially since they clearly cause more genital infections. According to a new study published in CMAJ Open, SGLT2 inhibitors are likely not causing urinary tract infections, but rather the increased urinary glucose concentration may be somehow linked to infection severity, with one exception, and that is with high doses of dapagliflozin, according to findings. Researchers conducted a systematic review and meta-analysis of 105 randomized controlled trials focused on eight SGLT2 inhibitors, including dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, luseogliflozin, remogliflozin, tofogliflozin, and ertugliflozin. All trials were required to compare the inhibitor to either placebo, no treatment, or an active antidiabetic control. Doses were categorized as either high or low.  In conclusion, they found that SGLT2 inhibitors do not increase the risk for urinary tract infections in people with type 2 diabetes.

Study assesses glycemic variability via continuous glucose monitoring and compares it against incidence of diabetic retinopathy to determine if correlation exists.

Development of diabetic retinopathy found to be significantly reduced.

Automatic information processing studied to help find diabetic retinopathy on a larger scale.

Increased awareness of nontraditional risk factors may decrease disease diagnosis.

Trial examines differences in glycemic control and quality of life when using different insulin delivery methods.

Small but frequent activity helps improve insulin concentrations and sensitivity in children with excess weight and obesity.

Quote of the Week!

“It is our attitude at the beginning of a difficult task which, more than anything else, will affect its successful outcome.”

….William James

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletter:

Michael Zaccaro, Pharm. D. Candidate 2019, LECOM School of Pharmacy

Angela Reyes, Pharm.D. Candidate, LECOM College of Pharmacy

Annahita Forghan, Pharm.D. Candidate 2019, LECOM College of Pharmacy

Your Friends in Diabetes Care
Steve, Dave, and Joy
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com